FIELD: medicine.
SUBSTANCE: disclosed is a liquid composition for stabilizing a conjugate of a double agonist GLP-1 receptor (glucagon-like peptide-1)/long-acting glucagon, containing from 18 nmol/ml to 940 nmol/ml of the GLP-1/glucagon double agonist peptide conjugate of Chemical Formula 1; from 5 mM to 25 mM acetic acid and its salt in an amount to maintain the pH of the liquid composition in range of 4.8 to 5.5; from 4% to 10% (wt./vol.) of sucrose; and from 0.01% to 0.1% (wt./vol.) of a nonionic surfactant selected from poloxamer, polysorbate and a combination thereof.
EFFECT: obtaining a stable liquid composition which provides storage of a long-acting peptide conjugate.
17 cl, 9 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION FOR TREATING HYPERLIPIDEMIA CONTAINING AN OXYNTOMODULIN DERIVATIVE | 2013 |
|
RU2768853C1 |
| CONJUGATE CONTAINING OXINTOMODULIN AND IMMUNOGLOBULIN FRAGMENT, AND ITS APPLICATION | 2012 |
|
RU2733544C2 |
| THERAPEUTIC USE OF LONG-ACTING TRIPLE AGONIST CONJUGATE HAVING ACTIVITIES ON ALL GLUCAGON/GLP-1/GIP RECEPTORS FOR TREATING LUNG DISEASE | 2020 |
|
RU2829342C1 |
| THERAPEUTIC USE OF GLUCAGON AND ITS COMBINATION | 2019 |
|
RU2838895C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING INSULIN AND GLUCAGON | 2019 |
|
RU2823246C2 |
| NOVEL OXYNTOMODULIN DERIVATIVES AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM FOR TREATING OBESITY | 2012 |
|
RU2739209C2 |
| PEPTIDE ANALOG OF ACYLATED OXYNTOMODULIN | 2018 |
|
RU2752787C1 |
| INSULIN ANALOGUE COMPLEX WITH REDUCED AFFINITY TO INSULIN RECEPTOR AND ITS USE | 2018 |
|
RU2779462C2 |
| NEW METHOD FOR OBTAINING LONG-ACTING DRUG CONJUGATE BY PRODUCING INTERMEDIATE | 2019 |
|
RU2805873C2 |
| IGG4 Fc FRAGMENT CONTAINING A MODIFIED HINGE REGION | 2014 |
|
RU2800558C1 |
